• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Greenbrier, Fortress Biotech And 3 Stocks To Watch Heading Into Monday

    7/8/24 3:10:02 AM ET
    $FBIO
    $GBX
    $NWGL
    $SAH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Railroads
    Industrials
    Get the next $FBIO alert in real time by email

    With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:

    • Wall Street expects The Greenbrier Companies, Inc. (NYSE:GBX) to report quarterly earnings at $1.14 per share on revenue of $928.73 million before the opening bell. Greenbrier shares gained 0.72% to $48.91 in the after-hours trading session.
    • Nature Wood Group Limited (NASDAQ:NWGL) said Jianjun Zeng is stepping down as CEO due to health reasons. The company named Hubei Song as its new CEO. Nature Wood Group shares gained 2% to $2.03 in after-hours trading.
    • Fortress Biotech, Inc. (NASDAQ:FBIO) reported a pause in the payment of dividends on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock. Fortress Biotech shares fell 2.8% to $1.75 in the after-hours trading session.

    Check out our premarket coverage here

    • Sonic Automotive, Inc. (NYSE:SAH) disclosed a cybersecurity incident impacting its dealer management and CRM systems. Sonic Automotive shares slipped 0.3% to $52.00 in after-hours trading.
    • Unicycive Therapeutics, Inc. (NASDAQ:UNCY) filed for the resale of up to 50 million shares by the selling stockholders. Unicycive Therapeutics shares fell 2% to $0.4480 in the after-hours trading session.

    Check This Out: How To Earn $500 A Month From Nvidia Stock

    Photo courtesy: The Greenbrier Company

    Get the next $FBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FBIO
    $GBX
    $NWGL
    $SAH

    CompanyDatePrice TargetRatingAnalyst
    Sonic Automotive Inc.
    $SAH
    3/4/2026Neutral
    BofA Securities
    Greenbrier Companies Inc.
    $GBX
    11/21/2025$38.00Sell
    Goldman
    Sonic Automotive Inc.
    $SAH
    11/12/2025$71.00Equal Weight
    Barclays
    Sonic Automotive Inc.
    $SAH
    11/7/2025$82.00Neutral → Buy
    Citigroup
    Sonic Automotive Inc.
    $SAH
    7/17/2025$82.00Overweight → Equal-Weight
    Stephens
    Sonic Automotive Inc.
    $SAH
    5/28/2025$76.00Buy
    The Benchmark Company
    Sonic Automotive Inc.
    $SAH
    4/23/2025$64.00Neutral
    Citigroup
    Unicycive Therapeutics Inc.
    $UNCY
    4/21/2025$6.00Buy
    Guggenheim
    More analyst ratings

    $FBIO
    $GBX
    $NWGL
    $SAH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Rusnak Paul P. bought $5,994,472 worth of SAH (100,000 units at $59.94), increasing direct ownership by 2% to 5,100,000 units (SEC Form 4)

    4 - SONIC AUTOMOTIVE INC (0001043509) (Issuer)

    2/18/26 6:46:07 PM ET
    $SAH
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Director Huffines James R bought $112,108 worth of shares (2,500 units at $44.84), increasing direct ownership by 22% to 13,909 units (SEC Form 4)

    4 - GREENBRIER COMPANIES INC (0000923120) (Issuer)

    8/11/25 5:19:09 PM ET
    $GBX
    Railroads
    Industrials

    PRESIDENT, CEO & CHAIRMAN Rosenwald Lindsay A Md bought $1,404,581 worth of shares (763,359 units at $1.84), increasing direct ownership by 26% to 3,657,264 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    9/25/24 4:45:04 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    $GBX
    $NWGL
    $SAH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

    SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. shoul

    3/18/26 8:30:00 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Greenbrier schedules second quarter fiscal 2026 earnings release and conference call

    LAKE OSWEGO, Ore., March 17, 2026 /PRNewswire/ -- The Greenbrier Companies, Inc. (NYSE:GBX) announced today it will be reporting its second quarter 2026 results after market on Tuesday, April 7, 2026. Shareholders and other interested parties are invited to listen to its financial results conference call at 2:00 p.m. PDT, live, either over the Internet or via dial in. Listeners can access the webcast and earnings release at the Greenbrier website, www.gbrx.com. To register for or access the webcast, click on the announcement shown on the home page of the website. The webcast will be archived for 30 days.Alternatively, dial-in numbers for the Conference Call are 1-888-317-6003 for domestic ca

    3/17/26 5:36:00 PM ET
    $GBX
    Railroads
    Industrials

    UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 9:24:14 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    $GBX
    $NWGL
    $SAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on Sonic Automotive

    BofA Securities resumed coverage of Sonic Automotive with a rating of Neutral

    3/4/26 8:42:56 AM ET
    $SAH
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Goldman initiated coverage on Greenbrier with a new price target

    Goldman initiated coverage of Greenbrier with a rating of Sell and set a new price target of $38.00

    11/21/25 8:08:57 AM ET
    $GBX
    Railroads
    Industrials

    Barclays initiated coverage on Sonic Automotive with a new price target

    Barclays initiated coverage of Sonic Automotive with a rating of Equal Weight and set a new price target of $71.00

    11/12/25 8:58:10 AM ET
    $SAH
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $FBIO
    $GBX
    $NWGL
    $SAH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Fortress Biotech Inc.

    SCHEDULE 13D/A - Fortress Biotech, Inc. (0001429260) (Subject)

    3/20/26 4:16:06 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Sonic Automotive Inc.

    DEF 14A - SONIC AUTOMOTIVE INC (0001043509) (Filer)

    3/6/26 4:26:20 PM ET
    $SAH
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    SEC Form DEFA14A filed by Sonic Automotive Inc.

    DEFA14A - SONIC AUTOMOTIVE INC (0001043509) (Filer)

    3/6/26 4:26:13 PM ET
    $SAH
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $FBIO
    $GBX
    $NWGL
    $SAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rosenwald Lindsay A Md

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    3/20/26 4:05:13 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Weiss Michael S

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    3/20/26 4:05:10 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Rusnak Paul P. bought $5,994,472 worth of SAH (100,000 units at $59.94), increasing direct ownership by 2% to 5,100,000 units (SEC Form 4)

    4 - SONIC AUTOMOTIVE INC (0001043509) (Issuer)

    2/18/26 6:46:07 PM ET
    $SAH
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $FBIO
    $GBX
    $NWGL
    $SAH
    Leadership Updates

    Live Leadership Updates

    View All

    Greenbrier Names Travis Williams as Head of Investor Relations

    LAKE OSWEGO, Ore., Jan. 13, 2026 /PRNewswire/ -- The Greenbrier Companies (NYSE:GBX), a leading supplier of railroad freight car equipment and services, today announced the appointment of Travis Williams as its new Head of Investor Relations, reporting to Michael Donfris, Chief Financial Officer. In this role, Williams is responsible for managing Greenbrier's interactions with the investment community, including institutional investors, equity research analysts, and other key stakeholders. With over 20 years of experience in investor relations, capital markets, and equity analysis, Travis brings extensive knowledge and a proven track record of enhancing shareholder engagement and driving lo

    1/13/26 4:15:00 PM ET
    $GBX
    Railroads
    Industrials

    Journey Medical to Join Russell 2000® and Russell 3000® Indexes

    SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

    6/24/25 8:30:29 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Greenbrier Announces Ted Baun as Next Chief Commercial Officer

    Joins Greenbrier with 30 years of rail industry experience Assumes Chief Commercial Officer role in January 2026 LAKE OSWEGO, Ore., May 21, 2025 /PRNewswire/ -- The Greenbrier Companies, Inc. (NYSE:GBX) (Greenbrier), a leading international supplier of equipment and services to global freight transportation markets, announced today that Ted Baun has joined Greenbrier's North American Commercial Team as Senior Vice President (SVP). He will become Chief Commercial Officer in January 2026, succeeding Tim Schitter, who will retire at year-end.  Baun brings more than 30 years of ex

    5/21/25 4:38:00 PM ET
    $GBX
    Railroads
    Industrials

    $FBIO
    $GBX
    $NWGL
    $SAH
    Financials

    Live finance-specific insights

    View All

    Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

    SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. shoul

    3/18/26 8:30:00 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Greenbrier schedules second quarter fiscal 2026 earnings release and conference call

    LAKE OSWEGO, Ore., March 17, 2026 /PRNewswire/ -- The Greenbrier Companies, Inc. (NYSE:GBX) announced today it will be reporting its second quarter 2026 results after market on Tuesday, April 7, 2026. Shareholders and other interested parties are invited to listen to its financial results conference call at 2:00 p.m. PDT, live, either over the Internet or via dial in. Listeners can access the webcast and earnings release at the Greenbrier website, www.gbrx.com. To register for or access the webcast, click on the announcement shown on the home page of the website. The webcast will be archived for 30 days.Alternatively, dial-in numbers for the Conference Call are 1-888-317-6003 for domestic ca

    3/17/26 5:36:00 PM ET
    $GBX
    Railroads
    Industrials

    UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 9:24:14 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    $GBX
    $NWGL
    $SAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:13:38 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:01:14 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 5:46:12 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care